Abstract
Systemic sclerosis is a multisystem autoimmune disease with potential lung manifestations that include pulmonary vascular and interstitial disease. Not only is interstitial lung disease the most common pulmonary manifestation, it is a major cause of morbidity and mortality in patients with systemic sclerosis. The risk of systemic sclerosis patients developing progressive interstitial lung disease is strongly associated with the presence of certain autoantibodies The most common lung injury pattern observed in systemic sclerosis-related interstitial lung disease is the fibrotic variant of nonspecific interstitial pneumonia. Because scleroderma renal crisis can now be effectively treated, recently, focus has turned toward how best to treat systemic sclerosis-related interstitial lung disease. Therapy usually involves an immunomodulatory regimen consisting of a steroid-sparing agent with or without glucocorticoids, and response to therapy is variable.
Keywords: Systemic sclerosis, scleroderma, pulmonary fibrosis, lung diseases, interstitial
Current Respiratory Medicine Reviews
Title: Systemic Sclerosis-Related Interstitial Lung Disease
Volume: 4 Issue: 3
Author(s): Samay Dalal, Aryeh Fischer and Jeffrey J. Swigris
Affiliation:
Keywords: Systemic sclerosis, scleroderma, pulmonary fibrosis, lung diseases, interstitial
Abstract: Systemic sclerosis is a multisystem autoimmune disease with potential lung manifestations that include pulmonary vascular and interstitial disease. Not only is interstitial lung disease the most common pulmonary manifestation, it is a major cause of morbidity and mortality in patients with systemic sclerosis. The risk of systemic sclerosis patients developing progressive interstitial lung disease is strongly associated with the presence of certain autoantibodies The most common lung injury pattern observed in systemic sclerosis-related interstitial lung disease is the fibrotic variant of nonspecific interstitial pneumonia. Because scleroderma renal crisis can now be effectively treated, recently, focus has turned toward how best to treat systemic sclerosis-related interstitial lung disease. Therapy usually involves an immunomodulatory regimen consisting of a steroid-sparing agent with or without glucocorticoids, and response to therapy is variable.
Export Options
About this article
Cite this article as:
Dalal Samay, Fischer Aryeh and Swigris J. Jeffrey, Systemic Sclerosis-Related Interstitial Lung Disease, Current Respiratory Medicine Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339808785161332
DOI https://dx.doi.org/10.2174/157339808785161332 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nailfold Capillaroscopy - Practical Implications for Rheumatology Practice
Current Rheumatology Reviews Mouse Models of Primary Biliary Cirrhosis
Current Pharmaceutical Design Pharmacological and Clinical Basis of Treatment of Familial Mediterranean Fever (FMF) with Colchicine or Analogues: An Update
Current Drug Targets - Inflammation & Allergy Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy Iontophoresis - An Approach for Controlled Drug Delivery: A Review
Current Drug Delivery Digital Ulcers in Systemic Sclerosis – Frequency, Subtype Distribution and Clinical Outcome
Current Rheumatology Reviews The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Systemic Sclerosis at the Cellular Level: Molecular Pathways of Pathogenesis and its Implication on Future Drug Design
Current Medicinal Chemistry Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Effectiveness of Topical Anti-scarring Agents and a Novel Combined Process on Cutaneous Scar Management
Current Pharmaceutical Design Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine The Use of Colchicine in Respiratory Diseases
Current Respiratory Medicine Reviews Emerging Therapeutic Approaches Based on Nanotechnology for the Treatment of Diseases Associated with Telomere Dysfunction
Mini-Reviews in Medicinal Chemistry Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) New Developments In Treatment After Lung Transplantation
Current Pharmaceutical Design Nailfold Capillaroscopy Within and Beyond the Scope of Connective Tissue Diseases
Current Rheumatology Reviews